Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

|<

<

1

2

3

4

5

6

7

8

9

10

11

12

13

14

>

>|

Found 91 Matches

Lamotrigine_V17R1_HussonUniversity_20210628
Model Files Publication
https://pubmed.ncbi.nlm.nih.gov/30460522/ Lamotrigine IR and XR formulations in adults and in children aged between 4 and 17 years. 1) The file is set as FO file (IR formulation), the ADAM model can be activated and the corresponding models, like the segregated transit time model are then available to simulate the XR formulation. 2) The model is using absolute scaling for UGT1A3 and UGT1A4. For V21 the absolute abundance data for UGT1A3 were updated and hence the corresponding ISEF may require adjustment if the file is used in later versions.
Search Score: 11
Levocetirizine_V14R1_AstraZeneca_20200327
Model Files Publication
Levocetirizine for pediatric predictions.
Search Score: 11
Lamivudine
Model Files Publication

Brand Name(s) include: Epivir

Disease: HIV

Drug Class: Nucleoside reverse transcriptase inhibitor

Date of Review: 2020

Number of Models Reviewed: 3

Number of Models added to the Repository: 3

The model at-a-glance

Version 13

 Publication

De Sousa Mendes, M., Hirt, D., Urien, S., Valade, E., Bouazza, N., Foissac, F., Blanche, S., Treluyer, J. M., & Benaboud, S. (2015). Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. British journal of clinical pharmacology, 80(5), 1031–1041.

 Simcyp Version

V13

 Published Model Application

Prediction of exposure in pregnancy

 Absorption Model

First Order
 Volume of Distribution Details

Full PBPK

 Route of Elimination
  • Renal Elimination
  • Includes uptake by OCT2 and efflux by MRP4 in the kidney

 Perpetrator DDI
  • None 

 Advantages and Limitations
  • Model developed in healthy volunteers and verified in pregnant women.

 Model Compound Files
  • v13_res_lamivudine_simcyp_mendex2015

Version 17

 

 Publication

De Sousa Mendes M, Chetty M. Are Standard Doses of Renally-Excreted Antiretrovirals in Older Patients Appropriate: A PBPK Study Comparing Exposures in the Elderly Population With Those in Renal Impairment. Drugs R D. 2019 Dec;19(4):339-350.

 Simcyp Version

V17

 Published Model Application

Prediction of exposure in renal impairment

 Absorption Model

First Order
 Volume of Distribution Details

Full PBPK

 Route of Elimination
  • Renal Elimination
  • Additional non-specific clearance

 Perpetrator DDI
  • None 

 Advantages and Limitations
  • Model developed to extrapolate elderly populations and renally impaired populations.
  • Model was verified in the elderly population

 Model Compound Files
  • v17_res_ lamivudine_simcyp_mendex2019

Version 18

 Publication

Shah, K., Fischetti, B., Cha, A., & Taft, D. R. (2020). Using PBPK Modeling to Predict Drug Exposure and Support Dosage Adjustments in Patients With Renal Impairment: An Example with Lamivudine. Current drug discovery technologies, 17(3), 387–396.

 Simcyp Version

V18

 Published Model Application

Prediction of exposure in renal impairment

 Absorption Model

First Order
 Volume of Distribution Details

Full (mechanistic kidney model)

 Route of Elimination
  • Renal Elimination
  • Includes uptake by OCT2 and efflux by MATE in the kidney

 Perpetrator DDI
  • None 

 Advantages and Limitations
  • Model developed to renally impaired populations.

 Model Compound Files
  • v18_res_ lamivudine_simcyp_shah2020
Search Score: 11
Lopinavir&Ritonavir_V13R2_USFDA_20190719
Model Files Publication
Compound files from publication: Physiologically Based Pharmacokinetic Modeling for Predicting the Effect of Intrinsic and Extrinsic Factors on Darunavir or Lopinavir Exposure Coadministered With Ritonavir Wagner, C., Zhao, P., Arya, V., Mullick, C., Struble, K. and Au, S (2017). https://doi.org/10.1002/jcph.936 /PMID#: 28569994 The compound file is the final model used for simulations in combination with ritonavir (submitted to repository referencing the same article). Correction: Ritonavir's pKa 2 should be 2.6, reported in Supp. Table 1 was 2.8 https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/jcph.936
Search Score: 11

|<

<

1

2

3

4

5

6

7

8

9

10

11

12

13

14

>

>|